MoonLake Immunotherapeutics (NASDAQ:MLTX) Holdings Lifted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 29.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 20,740 shares of the company’s stock after acquiring an additional 4,740 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in MoonLake Immunotherapeutics were worth $1,123,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in MLTX. Barclays PLC grew its holdings in MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after buying an additional 5,229 shares in the last quarter. Congress Asset Management Co. boosted its position in MoonLake Immunotherapeutics by 9.5% during the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company’s stock worth $3,953,000 after acquiring an additional 6,352 shares during the period. Rice Hall James & Associates LLC boosted its position in MoonLake Immunotherapeutics by 47.3% during the 4th quarter. Rice Hall James & Associates LLC now owns 111,133 shares of the company’s stock worth $6,018,000 after acquiring an additional 35,664 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of MoonLake Immunotherapeutics by 3.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock worth $460,000 after purchasing an additional 320 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of MoonLake Immunotherapeutics by 18.4% during the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company’s stock valued at $354,000 after purchasing an additional 1,013 shares during the period. Institutional investors own 93.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MLTX shares. Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They set an “outperform” rating and a $67.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Wedbush restated an “outperform” rating and set a $80.00 price target (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday. The Goldman Sachs Group decreased their price objective on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.67.

MoonLake Immunotherapeutics Stock Down 4.1%

Shares of MLTX stock opened at $38.54 on Wednesday. The stock has a 50-day simple moving average of $38.43 and a 200 day simple moving average of $44.97. The stock has a market capitalization of $2.47 billion, a P/E ratio of -29.88 and a beta of 1.31. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same quarter in the prior year, the business posted ($0.22) EPS. On average, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.